Tirzepatide (Mounjaro) Reimbursement Review CDA-AMC Canada's Drug Agency review of tirzepatide (Mounjaro), covering clinical evidence and price/reimbursement context for Canadian payers
Youll receive a partial dose at best
Given the large number of enzymes requiring NAD, it is speculated that many of the conditions due to defective enzymes might be rescued by niacin supplementation (5)
That includes medical monitoring, nutritional counseling, support with behavior changes and realistic expectations
Conclusions The therapeutic scope of GLP-1R agonists is expanding beyond traditional metabolic targets, highlighting its potential for headache and pain disorders
However, if it has been exposed to temperatures above 80F for more than a few hours, or if you are uncertain about the exposure time, it is safer to discard the medication and request a replacement